Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001265847 | SCV001444019 | pathogenic | Inborn genetic diseases | 2018-02-06 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003469496 | SCV004214331 | likely pathogenic | Aspartylglucosaminuria | 2022-06-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003469496 | SCV004272838 | pathogenic | Aspartylglucosaminuria | 2023-11-25 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn110Metfs*18) in the AGA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AGA are known to be pathogenic (PMID: 7627186, 11309371). This variant is present in population databases (rs764357395, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with AGA-related conditions. ClinVar contains an entry for this variant (Variation ID: 985108). For these reasons, this variant has been classified as Pathogenic. |